2C-B, Shulgin's 1974 invention, is now tested head-to-head against MDMA and psilocybin
The chemist Alexander Shulgin created 2C-B in 1974 and ranked it among his favourite compounds. A decade later it was sold as a substitute for ecstasy, and by the mid-1990s the United States had banned it. Now controlled clinical trials are measuring how it compares with MDMA and psilocybin.
Chemically, 2C-B is a phenethylamine, one of the 2C family, and was among the first of that group described in the scientific literature, in 1975. It acts as a potent partial agonist at serotonin 5-HT2 receptors, including the 5-HT2A receptor tied to psychedelic effects. It emerged as a designer drug in the mid-1980s and remains the best known of the 2C compounds. Relatives include DOB and 25B-NBOMe.
Shulgin, who catalogued it in his book PiHKAL, described it as offering rich sensory enhancement with little demand for introspection, and counted it among his six most important phenethylamines. Other users describe a blend of visual effects resembling LSD with a warmer, more sociable quality reminiscent of MDMA, which has earned it nicknames such as the beginner psychedelic. Such reports come with caveats: its dose-response curve is steep, so a small increase can bring an unexpectedly large jump in effects, and it can still produce bad trips.
Formal research gives a more measured picture. In a double-blind, placebo-controlled crossover trial, 24 healthy volunteers took three doses of 2C-B alongside MDMA and psilocybin. The highest 2C-B dose produced an overall drug effect comparable to MDMA but weaker than psilocybin, and like MDMA it raised emotional empathy. Only psilocybin triggered anxiety and bad drug effects relative to placebo. The 2C-B effects lasted about 4.9 hours, close to MDMA's 4.8 and shorter than psilocybin's 6.1, and MDMA raised heart rate and blood pressure most.
Other clinical work compared it directly with psilocybin and found fewer negative mood effects, less ego dissolution and less cognitive impairment, with equivalent visual changes. Findings on whether it genuinely produces MDMA-like emotional openness are mixed across studies. Its elimination half-life in the blood is about 1.3 hours. The trial authors framed their results as groundwork for choosing doses in future research, not as evidence of any treatment benefit.
Source: 2C-B
